Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy IDEXX Laboratories (IDXX) stocks in Canada

Learn how to easily invest in IDEXX Laboratories stocks.

IDEXX Laboratories is a diagnostics & research business based in the US. IDEXX Laboratories stocks (IDXX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $607.58 – a decrease of 3.44% over the previous week. IDEXX Laboratories employs 9,800 staff and has a trailing 12-month revenue of around $3.1 billion.

How to buy shares in IDEXX Laboratories

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IDXX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

IDEXX Laboratories stock price (NASDAQ:IDXX)

Use our graph to track the performance of IDXX stocks over time.

IDEXX Laboratories shares at a glance

Information last updated 2022-01-17.
Latest market close$511.15
52-week range$455.23 - $706.95
50-day moving average $612.51
200-day moving average $615.80
Wall St. target price$706.17
PE ratio 60.7192
Dividend yield N/A (0%)
Earnings per share (TTM) $8.72

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy IDEXX Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

IDEXX Laboratories price performance over time

Historical closes compared with the close of $511.15 from 2022-01-20

1 week (2022-01-14) -3.44%
1 month (2021-12-21) -18.09%
3 months (2021-10-21) -20.78%
6 months (2021-07-21) -23.77%
1 year (2021-01-21) 2.96%
2 years (2020-01-21) 79.45%
3 years (2019-01-18) 154.47%
5 years (2017-01-20) 329.97%

Is IDEXX Laboratories under- or over-valued?

Valuing IDEXX Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IDEXX Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

IDEXX Laboratories's P/E ratio

IDEXX Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 61x. In other words, IDEXX Laboratories shares trade at around 61x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

IDEXX Laboratories's PEG ratio

IDEXX Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.0203. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IDEXX Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

IDEXX Laboratories's EBITDA

IDEXX Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1 billion.

The EBITDA is a measure of a IDEXX Laboratories's overall financial performance and is widely used to measure a its profitability.

IDEXX Laboratories financials

Revenue TTM $3.1 billion
Operating margin TTM 29.28%
Gross profit TTM $1.6 billion
Return on assets TTM 25.88%
Return on equity TTM 12.65%
Profit margin 24.14%
Book value $8.89
Market capitalisation $44.9 billion

TTM: trailing 12 months

IDEXX Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IDEXX Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

IDEXX Laboratories's total ESG risk score

Total ESG risk: 29.79

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IDEXX Laboratories's overall score of 29.79 (as at 12/31/2018) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like IDEXX Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

IDEXX Laboratories's environmental score

Environmental score: 9.93/100

IDEXX Laboratories's environmental score of 9.93 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

IDEXX Laboratories's social score

Social score: 14.44/100

IDEXX Laboratories's social score of 14.44 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

IDEXX Laboratories's governance score

Governance score: 17.91/100

IDEXX Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that IDEXX Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

IDEXX Laboratories share dividends

We're not expecting IDEXX Laboratories to pay a dividend over the next 12 months.

Have IDEXX Laboratories's shares ever split?

IDEXX Laboratories's shares were split on a 2:1 basis on 15 June 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your IDEXX Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IDEXX Laboratories shares which in turn could have impacted IDEXX Laboratories's share price.

IDEXX Laboratories share price volatility

Over the last 12 months, IDEXX Laboratories's shares have ranged in value from as little as $455.23 up to $706.95. A popular way to gauge a stock's volatility is its "beta".

IDXX.US volatility(beta: 0.95)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEXX Laboratories's is 0.9473. This would suggest that IDEXX Laboratories's shares are less volatile than average (for this exchange).

IDEXX Laboratories overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site